GEORGE C. GRIFFITH, M.D., F.A.C.P.; ROBERT STRAGNELL, M.D.; DAVID C. LEVINSON, M.D.; FREDERICK J. MOORE, M.D.; ARNOLD G. WARE, Ph. D.
This content is PDF only. Please click on the PDF icon to access.
Thromboemboli are a frequent cause of death in patients with congestive heart failure. In 565 patients with rheumatic heart disease and congestive heart failure, autopsied at the Los Angeles County Hospital,1 thromboemboli were found in 30.3 per cent. In 114 patients thromboemboli were the direct cause of death, in 20 patients a contributory cause of death, and in 28 patients did not contribute to death. Despite this fact, anticoagulants have not been widely used as an adjuvant to routine therapy. Several groups2a, b, 3, 4 have studied this problem and report a 5.8 to 8 per cent reduction in mortality,
GRIFFITH GC, STRAGNELL R, LEVINSON DC, MOORE FJ, WARE AG. A STUDY OF THE BENEFICIAL EFFECTS OF ANTICOAGULANT THERAPY IN CONGESTIVE HEART FAILURE1. Ann Intern Med. ;37:867–887. doi: 10.7326/0003-4819-37-5-867
Download citation file:
Published: Ann Intern Med. 1952;37(5):867-887.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use